FDA 21 CFR Part 11 Password Requirements

FDA 21 CFR Part 11 is a U.S. Food and Drug Administration (FDA) regulation that establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. FDA 21 CFR Part 11 defines specific requirements for the management of passwords and user authentication in computerized systems having electronic signature capabilities.

FDA 21 CFR Part 11 password requirements are a set of controls mandated by the FDA to ensure the security and integrity of electronic records and electronic signatures, which rely on identification codes and passwords. The purpose of password requirements under FDA 21 CFR Part 11 is to ensure individual accountability, data integrity, and system security.

The main Part 11 password requirements include the use of unique identification codes and passwords for each system user, periodic revision of passwords, management of lost or compromised credentials, transaction safeguards, and initial as well as periodic testing of authentication devices.

To ensure compliance with FDA 21 CFR Part 11, companies must implement a combination of technical, administrative, and procedural controls, such as role-based access control, mandatory password changes, and formal procedures for password and account management.

SimplerQMS is an electronic Quality Management System (eQMS) designed for life sciences companies. SimplerQMS complies with FDA 21 CFR Part 11 by using unique user credentials, secure electronic signatures, role-based access, and automated audit trails, among others. SimplerQMS facilitates document control, training management, CAPA management, and audit management, among other functions, helping life-science companies maintain compliance with FDA and other life science requirements.

What Are the FDA 21 CFR Part 11 Password Requirements?

The FDA 21 CFR Part 11 password requirements are outlined below.

1. Unique Identification Codes and Passwords: FDA 21 CFR Part 11 requires each system user to have a unique identification code and password combination. The unique password and identification code ensure traceability of electronic signatures.
2. Periodic Review and Revision of Passwords: Organizations must establish procedures for periodic password revision to prevent password aging. Password revision reduces the risk of unauthorized access.
3. Loss Management and Deauthorization Procedures: FDA 21 CFR Part 11 mandates documented procedures for managing lost, stolen, or compromised credentials. Effective loss management safeguards data integrity and prevents unauthorized access.
4. Transaction Safeguards and Unauthorized Use Detection: Systems must incorporate mechanisms to detect and prevent unauthorized attempts to use passwords or identification codes. Access logs can capture such events, enabling investigation and corrective action.
5. Initial and Periodic Testing of Authentication Devices: FDA 21 CFR Part 11 requires initial and periodic testing of devices that verify identity. Testing authentication devices ensures that they operate correctly and have not been altered in an unauthorized manner.

1. Unique Identification Codes and Passwords

FDA 21 CFR Part 11 requires the use of unique identification codes and passwords to ensure that every individual who accesses systems that manage electronic records or signatures is uniquely identifiable. Each user must have a distinct username and password combination that is not shared or used by another person. Unique identification codes and password requirements apply to all computerized systems managing FDA-regulated records and signatures.

The unique identification and password requirement is important for compliance with Part 11 because it ensures accountability, enables meaningful audit trails, supports data integrity, and facilitates quality investigations. Without a unique identifier for each user, it becomes impossible to determine who performed specific actions, making electronic records unreliable.

The key elements of the unique identification and password requirement are listed below.

• Unique user identification code assigned to each individual.
• Secure password known only to the authorized user.
• System enforcement to prevent duplicate or shared credentials.

Failure to comply with this requirement can result in serious data integrity issues, compromising record authenticity and regulatory compliance, making electronic records untrustworthy.

The FDA has repeatedly cited companies for violations in this area. For instance, in Warning Letter 320-23-17, FDA noted that the Quality Unit “failed to adequately restrict access to analytical instruments; shared usernames and passwords were used.” Similarly, Warning Letter 320-24-43 highlighted that a “stand-alone gas chromatogram (GC) computer system lacked appropriate controls, such as an audit trail and individual log-in access,” and that “laboratory personnel used a shared password, located in an unsecured drawer”.

Organizations should configure all relevant computerized systems to enforce unique usernames and passwords for each user. Built-in system controls must prevent duplicate identification code–password combinations, and companies must prohibit shared access. Passwords should follow defined complexity rules, including minimum length and character variation, to strengthen authentication and maintain compliance with FDA expectations.

2. Periodic Review and Revision of Passwords

FDA 21 CFR Part 11 implies that organizations must ensure that passwords used to access computerized systems managing electronic records and signatures are periodically revised. The periodic password revision prevents aging, ensuring that access credentials remain secure over time.

The periodic password revision requirement is essential for compliance because it prevents unauthorized access by individuals who may have obtained a valid password through illicit means. By requiring users to change passwords periodically, organizations reduce the window of opportunity for misuse and strengthen the security of electronic signatures.

The main point of the Part 11 requirement for password revision is to define a specific schedule for password updates.

Failure to comply with periodic password review and revision requirements may expose organizations to data breaches and risks of electronic record tampering. FDA warning letters focus on the need to ensure password confidentiality, which relies on the regular review, update, and protection of login credentials. For example, Warning Letter 320-23-07 and Warning Letter 320-21-53 highlight system security provisions, stating the agency examines “whether unique usernames/passwords are always used, and their confidentiality safeguarded.”

A best practice for complying with password revision requirements is for organizations to implement a formal password policy that defines expiration intervals and to enforce that policy technically through the system configuration. The expiration period should balance frequency and complexity, since too frequent changes may encourage weaker, more predictable passwords. The password review and renewal process should align with the user account lifecycle, where password expiration tracking begins when an account is created or reactivated. Any password assigned by a system administrator must be used only once and immediately changed by the user to ensure confidentiality. Organizations should perform regular reviews to verify that access credentials are still valid and appropriate for each user’s current role and responsibilities.

3. Loss Management and Deauthorization Procedures

FDA 21 CFR Part 11 requires organizations to implement loss management procedures that promptly deauthorize any device or mechanism used to generate or store identification codes or passwords when they are lost, stolen, or potentially compromised.

The loss management and deauthorization requirement is critical for compliance because it prevents unauthorized access resulting from lost or stolen credentials.

The main elements of the loss management and deauthorization requirement are the following.

• Established procedures to deauthorize compromised tokens, cards, or devices electronically.
• Issuance of temporary or permanent password or code replacements with rigorous administrative control.
• Immediate response plans for managing lost or stolen credentials and documenting each incident.

Without prompt deactivation of compromised devices, unauthorized users could gain access to regulated systems, alter records, or falsify electronic signatures, leading to serious data integrity violations.

Organizations should establish a formal Standard Operating Procedure (SOP) for loss management and device deauthorization. Maintaining an authorization or access control matrix listing each employee’s system access rights helps ensure timely action when credentials need to be revoked. Employees should be trained to immediately report any lost, stolen, or compromised tokens, cards, or authorization devices. Timely communication and prompt deactivation of affected accounts safeguard electronic records and support continuous compliance with FDA 21 CFR Part 11.

4. Transaction Safeguards and Unauthorized Use Detection

FDA-regulated companies under Part 11 are obliged to establish transaction safeguards that prevent unauthorized use of identification codes and passwords. Part 11 requires mechanisms to detect and report any attempted or actual unauthorized system access to the designated system security unit.

The transaction safeguards and unauthorized use detection requirements are essential for compliance because they protect the integrity, authenticity, and confidentiality of electronic records and signatures. Effective safeguards prevent tampering, ensure accountability, and maintain confidence that all electronic data and signatures originate from authorized individuals.

The main points of transaction safeguards and unauthorized use detection are listed below.

• Technical transaction safeguards that may include account lockout mechanisms, session timeouts, and multi-factor authentication.
• Detection mechanisms that identify and record unauthorized access attempts.
• Prompt notification and escalation procedures for any suspected security breaches.

If transaction safeguards and unauthorized use detection requirements are not met, organizations face increased risk of unauthorized data alteration, forgery, or falsification of electronic signatures. Unauthorized access compromises audit trail reliability and the ability to prove data authenticity.

During FDA inspections, inadequate access controls are a frequent significant observation. For example, in Case #656056, the agency observed that “laboratory equipment used to generate analytical data for finished drug product release lacked restricted access and sufficient controls…some laboratory staff had administrator rights, allowing uncontrolled access to delete or modify high-performance liquid chromatography (HPLC) files. There was no mechanism to facilitate traceability of individuals who deleted or modified data generated by computerized systems.”

To maintain compliance with FDA expectations, companies should configure role-based access control to restrict privileges based on defined roles and responsibilities. Computerized systems must include technical safeguards and alert mechanisms that notify designated security personnel of suspicious activities, such as multiple failed login attempts. Automatic account lockout and forced password reset procedures should be activated in such cases.

5. Initial and Periodic Testing of Authentication Devices

FDA 21 CFR Part 11 mandates that devices used to bear or generate identification code or password information undergo initial and periodic testing. The initial and periodic testing verifies that the authentication devices function properly and have not been altered in an unauthorized manner.

The initial and periodic testing requirement is vital for compliance because it confirms that the device accurately identifies authorized users.

The key element of the initial and periodic testing requirement is the qualification of the identification device upon initial deployment and its periodic requalification or testing during its operational life. Both steps verify that the device continues to meet its intended function and complies with the system’s security and data integrity requirements.

Failure to meet the initial and periodic testing requirements can lead to authentication errors or device malfunction. Proactive testing helps identify failing devices before they cause unexpected downtime or allow unauthorized entry.

The companies should implement initial and periodic testing of authentication devices by managing the authentication devices as part of their controlled equipment inventory. Each device should be initially qualified according to the manufacturer’s instructions. Periodic re-testing should follow a defined schedule based on the manufacturer’s recommendations, usage frequency, and associated risk. Any detected malfunction or unauthorized modification of authentication devices must be immediately documented and corrected.

What Are the Best Practices for Implementing 21 CFR Part 11 Password Requirements?

The best practices for implementing 21 CFR Part 11 password requirements are given below.

• Prohibit Shared Accounts: Prohibit shared, generic, or default accounts such as “analyst” or “admin”. Administrator privileges must be granted only to independent, authorized personnel to protect data integrity.
• Keep an Access Control Matrix: Maintain an up-to-date matrix of all user accesses, ensuring each access right corresponds to specific job duties and responsibilities.
• Enforce Password Complexity Rules: Implement password policies requiring a minimum length and a mix of uppercase and lowercase letters, numbers, and special characters to enhance resistance against unauthorized access attempts.
• Ensure Credential Uniqueness: Configure systems to prevent users from sharing the same username or password and disallow the reuse of previous passwords to preserve integrity.
• Set Password Expiration Periods: Require users to update passwords regularly to mitigate risks associated with password aging or compromise.
• Secure Password Recovery: Allow only system administrators to reset passwords. Any password provided by the administrator must be temporary and changed immediately by the user after the first login.
• Enforce Account Lockout Policy: Set up automatic account lockouts after a defined number of unsuccessful login attempts to prevent brute-force access attempts.
• Set Session Timeout: Implement automatic logout after a defined period of user inactivity to prevent unauthorized use of unattended workstations.
• Establish Written Procedures: Create and maintain documented procedures covering password creation, complexity, expiration, reset, and revocation processes to ensure consistency.
• Train Employees: Provide regular training on password management, emphasizing user accountability for safeguarding credentials and promptly reporting suspicious activity or lost, stolen, or compromised credentials.
• Maintain Audit Trails: Record all password-related activities, such as password changes, resets, and failed login attempts, in tamper-evident audit trails to ensure traceability.

How Can You Ensure Compliance with FDA 21 CFR Part 11?

To ensure compliance with FDA 21 CFR Part 11, companies must identify which computerized systems manage electronic records and signatures, validate these systems, and ensure data integrity throughout each electronic record lifecycle.

The main steps to ensure compliance with FDA 21 CFR Part 11 are the following.

1. Define FDA 21 CFR Part 11 Applicability: Determine which systems and processes fall under the Part 11 scope.
2. Conduct an FDA 21 CFR Part 11 Gap Assessment: Evaluate existing systems against Part 11 requirements to identify compliance gaps and create an action plan for remediation.
3. Validate Electronic Systems: Perform system validation to confirm that all computerized systems function consistently and reliably as intended.
4. Activate Audit Trails: Ensure that every data entry, modification, or deletion is automatically captured, including the user’s identity, timestamp, and reason for change to ensure data integrity.
5. Define and Control User Access: Configure role-based access to limit users’ system privileges to the required level to perform their duties and prevent unauthorized activities.
6. Establish Electronic Signature Controls: Implement electronic signature controls that securely link signatures to individual records and confirm signers’ identities.
7. Develop and Maintain a Robust QMS: Develop and maintain a structured QMS with defined procedures and roles. Handle the electronic records and signatures as part of the QMS.
8. Establish SOPs and Documentation: Define written procedures covering system access, data entry, audit trails, electronic signatures, and security management to maintain operational control.
9. Train Personnel on SOPs and Part 11 Requirements: Provide ongoing training to ensure users understand system functionality, security, responsibilities, and compliance obligations.
10. Ensure Data Retention and Accessibility: Maintain electronic records in secure, retrievable formats throughout their retention period to support audits and inspections.
11. Perform Regular Internal Audits and Reviews: Conduct periodic audits to verify adherence to Part 11 controls and to identify areas for continuous improvement.
12. Monitor Regulatory Updates: Track FDA updated regulatory requirements and new guidance published to maintain ongoing compliance.

How Does SimplerQMS Ensure Compliance with FDA 21 CFR Part 11?

SimplerQMS is an electronic Quality Management System (eQMS) designed specifically for life science companies, providing a validated, cloud-based platform with built-in 21 CFR Part 11 compliant controls.

SimplerQMS is a 21 CFR Part 11 compliant software that allows life science companies to maintain electronic records and signatures that are secure, attributable, and readily available for inspections or audits.

SimplerQMS fulfills the following 21 CFR Part 11 requirements.

• Audit Trail Functionality: Within SimplerQMS, all modifications are automatically recorded, capturing user ID and timestamp to ensure full traceability.
• Automated Time-Stamping: SimplerQMS generates accurate, time-stamped entries for all system activities to preserve data integrity.
• Electronic Signature Support: SimplerQMS supports secure, verifiable electronic signatures, linking each signature to its respective record.
• User Access Control: SimperQMS platform enforces role-based permissions and unique user credentials to prevent unauthorized system access and maintain accountability.
• System Validation: SimplerQMS is delivered as a fully validated solution, according to GAMP 5, with re-validation provided when necessary.
• Document Control: SimplerQMS streamlines document control by simplifying review and approval processes, relating documents through metadata cards, and protecting documents from unauthorized access.
• Workflow Management: Within the SimplerQMS platform, standardized review and approval workflows are applied, ensuring a controlled sequence of steps.
• Data Retention and Retrieval: Within the SimplerQMS software, records are safely stored in a secure, retrievable format to meet FDA retention and inspection-readiness requirements.

SimplerQMS supports compliance across a broad range of QMS processes, offering robust document control, change management, training management, CAPA management, and audit management, among other modules. Each module within SimplerQMS further supports life-science companies to meet FDA Part 11 and EU Annex 11, FDA Part 210-211, Part 820, EU-GMP, EU MDR, EU IVDR, and other requirements.